• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Digestion >In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors acid pump antagonists or indomethacin-phosphatidylcholine
【2h】

In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors acid pump antagonists or indomethacin-phosphatidylcholine

机译：质子泵抑制剂酸泵拮抗剂或吲哚美辛磷脂酰胆碱对吲哚美辛诱导的小肠损伤的体外和体内保护

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/AimsProton pump inhibitors (PPI) are widely used to prevent NSAID-induced peptic ulcers. NSAIDs produce small intestinal injury and some PPIs have been reported to have a protect against NSAID-induced small bowel injury in rats. To compare PPIs, revaprazan, and phosphatidylcholine-associated indomethacin (Indo-PC) for protection against indomethacin (Indo) induced small bowel injury. Methods: Rat intestinal epithelial cells (IEC-6) were pretreated with omeprazole, lansoprazole or revaprazan prior to exposure to Indo or Indo-PC. Cell viability was assessed by methyl thiazolyl tetrazolium assay. Omeprazole, lansoprazole or revaprazan were administered orally to rats prior to vehicle or Indo. Indo-PC was administered alone. After 24h small intestinal erosions were counted; intestinal bleeding was assessed as hemoglobin concentration of small intestinal fluid. Results: Omeprazole, lansoprazole and revaprazan did not protect against Indo-induced IEC-6 cell injury. Indo-PC was less damaging in vitro than Indo alone. In vivo neither omeprazole nor lansoprazole protected against Indo-induced small bowel injury, however, revaprazan pretreatment and Indo-PC resulted in significantly fewer erosions (>50% reduction) or bleeding (>80% reduction).
机译：背景/目的质子泵抑制剂（PPI）被广泛用于预防NSAID引起的消化性溃疡。 NSAIDs会产生小肠损伤，据报道某些PPI具有保护作用，可抵御NSAID诱导的大鼠小肠损伤。为了比较PPI，瑞伐拉赞和磷脂酰胆碱相关的吲哚美辛（Indo-PC）对吲哚美辛（Indo）引起的小肠损伤的保护作用。方法：在暴露于Indo或Indo-PC之前，先用奥美拉唑，兰索拉唑或瑞伐拉赞预处理大鼠肠上皮细胞（IEC-6）。通过甲基噻唑基四唑鎓测定法评估细胞活力。在媒介物或印度之前，先向大鼠口服奥美拉唑，兰索拉唑或瑞伐拉赞。单独使用Indo-PC。 24小时后，计算出小肠糜烂。肠道出血被评估为小肠液中血红蛋白浓度。结果：奥美拉唑，兰索拉唑和瑞伐拉赞不能抵抗印度诱导的IEC-6细胞损伤。与单独使用Indo相比，Indo-PC在体外的损害较小。在体内，奥美拉唑和兰索拉唑均不能预防印度引起的小肠损伤，但是，瑞伐拉赞预处理和印度-PC可以显着减少糜烂（减少50％以上）或出血（减少80％以上）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号